Tildrakizumab for the treatment of exfoliative cheilitis

Yıl 2023, Cilt: 6 Sayı: 1, 19 - 21, 31.01.2023

Timothy Cowan Nada Abu Alrub Anna Wilson Mani Makhija Dedee Murrell

https://doi.org/10.33204/mucosa.1209480

Öz

Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.

Anahtar Kelimeler

tildrakizumab, interleukin-23, biologic, cheilitis, dermatology

Eksfolyatif keilit tedavisinde tildrakizumab

Öz

Anahtar Kelimeler

biyolojik, keilit, tildrakizumab, interlökin-23, dermatoloji

Kaynakça

• Cai L, Wei J, Ma D, et al. Predisposition of hypersensitivity in patients with exfoliative cheilitis. J Dent Sci 2022;17:476-81.
• Georgakopoulou E, Loumou P, Grigoraki A, Panagiotopoulos A. Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%. Med Oral Patol Oral Cir Bucal 2021;26:e357-e60.
• Liu J, Shi L, Wang X, et al. Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration. J Oral Pathol Med 2021;50:251-9.
• Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005;141:1080-2.
• Gueutier A, Leducq S, Joly A, Picon L, Vaillant L, Samimi M. Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors. Int J Dermatol 2019;58:e236-e7.
• Taxonera C, Alba C, Colmenares M, Olivares D, Rey E. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review. Therap Adv Gastroenterol 2020;27:13.